Selpercatinib
Phase 1/2Active 0 views this week 0 watching💤 Quiet
Interest: 36/100
36
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Medullary Thyroid Cancer
Conditions
Medullary Thyroid Cancer, Infantile Myofibromatosis, Infantile Fibrosarcoma, Papillary Thyroid Cancer, Soft Tissue Sarcoma
Trial Timeline
Jun 13, 2019 → May 1, 2029
NCT ID
NCT03899792About Selpercatinib
Selpercatinib is a phase 1/2 stage product being developed by Eli Lilly for Medullary Thyroid Cancer. The current trial status is active. This product is registered under clinical trial identifier NCT03899792. Target conditions include Medullary Thyroid Cancer, Infantile Myofibromatosis, Infantile Fibrosarcoma.
What happened to similar drugs?
1 of 4 similar drugs in Medullary Thyroid Cancer were approved
Approved (1) Terminated (1) Active (2)
Hype Score Breakdown
Clinical
9
Activity
12
Company
15
Novelty
0
Community
0
Clinical Trials (9)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03906331 | Pre-clinical | Completed |
| NCT05324124 | Phase 1 | Completed |
| NCT05136404 | Phase 1 | Completed |
| NCT05089019 | Phase 1 | Completed |
| NCT04280081 | Phase 2 | Active |
| NCT03899792 | Phase 1/2 | Active |
| NCT05338515 | Phase 1 | Completed |
| NCT05469100 | Phase 1 | Completed |
| NCT05436912 | Phase 1 | Completed |
Competing Products
9 competing products in Medullary Thyroid Cancer
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Selpercatinib + Cabozantinib + Vandetanib | Eli Lilly | Phase 3 | 44 |
| Pralsetinib + Cabozantinib + Vandetanib | Roche | Phase 3 | 32 |
| • TF2 and 68 Ga-IMP-288 | Gilead Sciences | Phase 1/2 | 32 |
| Caprelsa | Sanofi | Pre-clinical | 26 |
| Vandetanib 300mg | Sanofi | Phase 1/2 | 32 |
| Vandetanib | Sanofi | Phase 3 | 40 |
| vandetanib + omeprazole + ranitidine | Sanofi | Phase 1 | 29 |
| Cabozantinib (XL184) 140 mg + Cabozantinib (XL184) 60 mg + Placebo tablet + Placebo capsule | Exelixis | Approved | 44 |
| cabozantinib | Exelixis | Pre-clinical | 23 |